To receive Noxxon’s real time information, please send a request to This email address is being protected from spambots. You need JavaScript enabled to view it.


Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. NOXXON disavows any obligation to update the information contained in such press releases after the date of their issuance.

Filter: NOX-A12 (olaptesed) | NOX-E36 (emapticap) | all


2019, June 24
8:00 a.m.
NOXXON announces leading international pharma to evaluate NOX-A12 in new indication

2019, April 01
7:00 p.m.
NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019

2019, February 28
7:00 p.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting

2019, February 27
6:00 p.m.
NOXXON files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer

2018, December 14
12:30 p.m.
NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients

2018, December 10
8:00 a.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at ESMO immuno-oncology congress on December 13-16, 2018

2018, November 21
8:00 a.m.
NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer

2018, October 26
8:00 a.m.
NOXXON to present top-line efficacy data from NOX-A12 / Keytruda combination trial in December as planned at ESMO Immuno-Oncology Conference

2018, October 02
6:00 p.m.
NOXXON presents top-line data from NOX-A12 monotherapy part of ongoing metastatic colorectal and pancreatic cancer trial

2018, September 19
8:00 a.m.
NOXXON to present clinical trial data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 'Translating Science into Survival'

2018, September 03
8:00 a.m.
NOXXON announces completion of patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial

2018, June 28
8:00 p.m.
NOXXON provides update on patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial

2018, May 29
8:00 a.m.
NOXXON provides clinical update prior to American Society of Clinical Oncology (ASCO) annual conference

2018, May 15
6:00 p.m.
NOXXON to present clinical trial update at BioEquity Europe

2017, October 03NOXXON Publishes Preclinical Proof-Of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors

2017, September 28NOXXON provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12

2017, July 04NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer

2017, May 16NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial

2016, December 15NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer

2016, December 05NOXXON Pharma announces new preclinical data showing synergy of lead compound NOX-A12 with natural killer (NK) Cell mediated therapies

2016, October 10NOXXON Pharma demonstrates synergies between NOX-A12 and therapies working through T cells or NK cells

2014, December 05Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference

2014, September 26Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models

2014, September 23NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment

2014, June 13NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients

2013, December 09NOXXON presenting at ASH 2013

2012, September 26NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma

2012, July 11NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia

2012, April 4NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

2011, December 12NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I

2010, September 22NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12

2010, May 3NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12

2009, November 2NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12

2009, September 3NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12